BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Teng Z, Gupta N, Hua Z, Liu G, Samnotra V, Venkatakrishnan K, Labotka R. Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development. Clin Transl Sci 2018;11:218-25. [PMID: 29168990 DOI: 10.1111/cts.12524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Upreti VV, Venkatakrishnan K. Model‐Based Meta‐Analysis: Optimizing Research, Development, and Utilization of Therapeutics Using the Totality of Evidence. Clin Pharmacol Ther 2019;106:981-92. [DOI: 10.1002/cpt.1462] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Leil TA, Lu Y, Bouillon-Pichault M, Wong R, Nowak M. Model-Based Meta-Analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development. Clin Pharmacol Ther 2021;109:517-27. [PMID: 32860421 DOI: 10.1002/cpt.2023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Alhaj-Suliman SO, Milavetz G, Salem AK. Model-based Meta-analysis to Compare Primary Efficacy-endpoint, Efficacy-time Course, Safety, and Tolerability of Opioids Used in the Management of Osteoarthritic Pain in Humans. Curr Drug Metab 2020;21:390-9. [PMID: 32407270 DOI: 10.2174/1389200221666200514130441] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Gupta N, Hanley MJ, Diderichsen PM, Yang H, Ke A, Teng Z, Labotka R, Berg D, Patel C, Liu G, van de Velde H, Venkatakrishnan K. Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. Clin Pharmacol Ther 2019;105:376-87. [PMID: 29446068 DOI: 10.1002/cpt.1047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Chen X, Wang DD, Li ZP. Analysis of time course and dose effect of tacrolimus on proteinuria in lupus nephritis patients. J Clin Pharm Ther 2021;46:106-13. [PMID: 32974902 DOI: 10.1111/jcpt.13260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Ryeznik Y, Sverdlov O, Svensson EM, Montepiedra G, Hooker AC, Wong WK. Pharmacometrics meets statistics-A synergy for modern drug development. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 34318621 DOI: 10.1002/psp4.12696] [Reference Citation Analysis]
7 Chan P, Peskov K, Song X. Applications of Model-Based Meta-Analysis in Drug Development. Pharm Res 2022. [PMID: 35174432 DOI: 10.1007/s11095-022-03201-5] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]